Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2076-2082, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (29)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karmatschek, M.
Right arrow Articles by Armbruster, F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karmatschek, M.
Right arrow Articles by Armbruster, F. P.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:2076-2082.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Improved purification of human bone sialoprotein and development of a homologous radioimmunoassay

Markus Karmatschek1,a, Ina Maier1, Markus J. Seibel2, Henning W. Woitge2, Reinhard Ziegler2 and Franz P. Armbruster1

1 Immundiagnostik GmbH, Wiesenstr. 4, 64625 Bensheim, Germany.

2 Department of Medicine, Division of Endocrinology and Metabolism, University of Heidelberg Medical School, Bergheimerstr. 58, 69115 Heidelberg, Germany.
a Author for correspondence. Fax Int. +49-6251-39084.

Bone sialoprotein (BSP) is a phosphorylated skeletal glycoprotein. Here we describe a new procedure for the purification of BSP involving wide-pore reversed-phase HPLC, and the development of a homologous RIA for human BSP. The immunoassay showed linearity between 3 and 120 µg/L, a lower detection limit of 0.7 µg/L, and a mean recovery rate of 99.4%. Intraassay variation was 7.0% (mean = 10.9 µg/L) and 6.1% (mean = 38.8 µg/L), and interassay variation was 9.2% (mean = 11.1 µg/L) and 9.4% (mean = 39.0 µg/L). No cross-reactivity was detected with osteocalcin, osteonectin, or bone alkaline phosphatase. Preliminary clinical evaluation in healthy controls (n = 90) showed a mean serum BSP concentration of 12.1 ± 5.0 µg/L (±SD). BSP was significantly increased in patients with Paget disease of bone, primary and secondary hyperparathyroidism, and also in subjects with renal failure without skeletal involvement. Impairment of hepatic function did not affect serum BSP concentrations.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
H. W. Woitge, H. Oberwittler, S. Heichel, A. Grauer, R. Ziegler, and M. J. Seibel
Short- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone
Clin. Chem., May 1, 2000; 46(5): 684 - 690.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. J. Diel, E.-F. Solomayer, M. J. Seibel, J. Pfeilschifter, H. Maisenbacher, C. Gollan, M. Pecherstorfer, R. Conradi, G. Kehr, E. Boehm, et al.
Serum Bone Sialoprotein in Patients with Primary Breast Cancer Is a Prognostic Marker for Subsequent Bone Metastasis
Clin. Cancer Res., December 1, 1999; 5(12): 3914 - 3919.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Wuttke, S. Muller, D. P. Nitsche, M. Paulsson, F.-G. Hanisch, and P. Maurer
Structural Characterization of Human Recombinant and Bone-derived Bone Sialoprotein. FUNCTIONAL IMPLICATIONS FOR CELL ATTACHMENT AND HYDROXYAPATITE BINDING
J. Biol. Chem., September 21, 2001; 276(39): 36839 - 36848.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.